Literature DB >> 30022447

CD147 (EMMPRIN) controls malignant properties of breast cancer cells by interdependent signaling of Wnt and JAK/STAT pathways.

Nadine Knutti1, Otmar Huber1, Karlheinz Friedrich2.   

Abstract

EMMPRIN (extracellular matrix metalloproteinase inducer, EMN, CD147) is a member of the immunoglobulin superfamily expressed in numerous cell types both as a soluble and a membrane-spanning glycoprotein. It is involved in many physiological processes, as well as in cancer. This study addresses mechanisms of crosstalk between EMN-driven cancer-related cellular responses and the canonical Wnt-pathway in MCF-7 breast carcinoma cells. Genetic knockdown of EMN in MCF-7 resulted in characteristic changes in cellular shape, organization of the actin cytoskeleton and malignancy profile, indicating that EMN expression represses cell motility, but, in contrast, exerts a stimulatory effect on cell proliferation and invasive properties. Increased invasiveness coincided with elevated expression of Wnt-target genes and established invasion driver matrix metalloproteinase MMP14. Activation of the downstream Wnt-pathway by means of heterologous β-catenin and/or TCF-4 expression, through inhibition of GSK-3β by LiCl treatment, or by cell stimulation with insulin-like growth factor-1 (IGF-1) resulted in increased EMN expression. EMN over-expression raised the ratio of the two opposing Wnt pathway-driven transcription factors Sp1 and Sp5, leading to stimulation of the EMN promoter. Furthermore, the EMN promoter was activated by a feed-forward circuit involving an EMN-dependent drop in expression of the repressive signal transducer and activator of transcription 1 (STAT1). Taken together, we show that the influence of EMMPRIN on malignancy-related properties of breast cancer cells is functionally connected to both Wnt- and JAK/STAT pathways.

Entities:  

Keywords:  Breast cancer; EMN; Feed-forward regulation; STAT1; Sp5; Wnt pathway

Mesh:

Substances:

Year:  2018        PMID: 30022447     DOI: 10.1007/s11010-018-3406-9

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  6 in total

1.  Dual effects of an anti-CD147 antibody for Esophageal cancer therapy.

Authors:  Miao Wang; Shuai Zhang; Qian Sun; Xiangmin Yang; Yu Wang; Runze Shang; Yumeng Zhu; Hui Yao; Yu Li
Journal:  Cancer Biol Ther       Date:  2019-08-14       Impact factor: 4.742

2.  Pan-Cancer Analysis, Reveals COVID-19-Related BSG as a Novel Marker for Treatment and Identification of Multiple Human Cancers.

Authors:  Tao Huang; Wei-Ying He
Journal:  Front Cell Dev Biol       Date:  2022-05-13

3.  Soluble CD147 (BSG) as a Prognostic Marker in Multiple Myeloma.

Authors:  Piotr Łacina; Aleksandra Butrym; Diana Frontkiewicz; Grzegorz Mazur; Katarzyna Bogunia-Kubik
Journal:  Curr Issues Mol Biol       Date:  2022-01-14       Impact factor: 2.976

4.  CD147 promotes collective invasion through cathepsin B in hepatocellular carcinoma.

Authors:  Shi-Jie Wang; Dong Chao; Wei Wei; Gang Nan; Jia-Yue Li; Fen-Ling Liu; Ling Li; Jian-Li Jiang; Hong-Yong Cui; Zhi-Nan Chen
Journal:  J Exp Clin Cancer Res       Date:  2020-07-29

5.  MicroRNA-129-1-3p Represses the Progression of Triple-Negative Breast Cancer by Targeting the GRIN2D Gene.

Authors:  Qi Li; Zehui Gu; Qi Tan; Liqun Ren; Suxian Chen
Journal:  Biomed Res Int       Date:  2022-03-07       Impact factor: 3.411

6.  BSG (CD147) Serum Level and Genetic Variants Are Associated with Overall Survival in Acute Myeloid Leukaemia.

Authors:  Piotr Łacina; Aleksandra Butrym; Eliza Turlej; Martyna Stachowicz-Suhs; Joanna Wietrzyk; Grzegorz Mazur; Katarzyna Bogunia-Kubik
Journal:  J Clin Med       Date:  2022-01-10       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.